146 related articles for article (PubMed ID: 3291971)
21. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.
Baker E; Vitolo ML; Webb J
Biochem Pharmacol; 1985 Sep; 34(17):3011-7. PubMed ID: 4038321
[TBL] [Abstract][Full Text] [Related]
22. The role of oxidative stress in the toxicity of pyridoxal isonicotinoyl hydrazone (PIH) analogues.
Buss JL; Neuzil J; Ponka P
Biochem Soc Trans; 2002 Aug; 30(4):755-7. PubMed ID: 12196187
[TBL] [Abstract][Full Text] [Related]
23. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
[TBL] [Abstract][Full Text] [Related]
24. Pyridoxal isonicotinoyl hydrazone. Effective iron chelation after oral administration.
Brittenham GM
Ann N Y Acad Sci; 1990; 612():315-26. PubMed ID: 2291560
[No Abstract] [Full Text] [Related]
25. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity.
Simunek T; Sterba M; Popelova O; Kaiserova H; Potacova A; Adamcova M; Mazurova Y; Ponka P; Gersl V
Hemoglobin; 2008; 32(1-2):207-15. PubMed ID: 18274998
[TBL] [Abstract][Full Text] [Related]
26. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilize iron from reticulocytes in vitro: reappraisal of reported partition coefficients.
Edward JT; Chubb FL; Sangster J
Can J Physiol Pharmacol; 1997 Dec; 75(12):1362-8. PubMed ID: 9534947
[TBL] [Abstract][Full Text] [Related]
27. Hydrolysis of pyridoxal isonicotinoyl hydrazone and its analogs.
Buss JL; Ponka P
Biochim Biophys Acta; 2003 Jan; 1619(2):177-86. PubMed ID: 12527114
[TBL] [Abstract][Full Text] [Related]
28. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
Becker E; Richardson DR
J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
[TBL] [Abstract][Full Text] [Related]
29. Pyridoxal isonicotinoyl hydrazone inhibits iron-induced ascorbate oxidation and ascorbyl radical formation.
Maurício AQ; Lopes GK; Gomes CS; Oliveira RG; Alonso A; Hermes-Lima M
Biochim Biophys Acta; 2003 Mar; 1620(1-3):15-24. PubMed ID: 12595068
[TBL] [Abstract][Full Text] [Related]
30. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone.
Cikrt M; Ponka P; Necas E; Neuwirt J
Br J Haematol; 1980 Jun; 45(2):275-83. PubMed ID: 7437326
[TBL] [Abstract][Full Text] [Related]
31. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process.
Richardson DR
Biochim Biophys Acta; 1997 May; 1320(1):45-57. PubMed ID: 9186779
[TBL] [Abstract][Full Text] [Related]
32. Pyridoxal Isonicotinoyl Hydrazone Improves Neurological Recovery by Attenuating Ferroptosis and Inflammation in Cerebral Hemorrhagic Mice.
Zhang H; Wen M; Chen J; Yao C; Lin X; Lin Z; Ru J; Zhuge Q; Yang S
Biomed Res Int; 2021; 2021():9916328. PubMed ID: 34541001
[TBL] [Abstract][Full Text] [Related]
33. The interaction of pyridoxal isonicotinoyl hydrazone (PIH) and salicylaldehyde isonicotinoyl hydrazone (SIH) with iron.
Chen YL; Kong X; Xie Y; Hider RC
J Inorg Biochem; 2018 Mar; 180():194-203. PubMed ID: 29329026
[TBL] [Abstract][Full Text] [Related]
34. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II).
Richardson DR; Hefter GT; May PM; Webb J; Baker E
Biol Met; 1989; 2(3):161-7. PubMed ID: 2490071
[TBL] [Abstract][Full Text] [Related]
35. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone.
Ponka P; Grady RW; Wilczynska A; Schulman HM
Biochim Biophys Acta; 1984 Dec; 802(3):477-89. PubMed ID: 6509088
[TBL] [Abstract][Full Text] [Related]
36. A lipophilic iron chelator induces an enhanced proliferation of human erythroleukaemia (HEL) cells.
Ekblom P; Landschulz W; Andersson LC
Scand J Haematol; 1986 Mar; 36(3):258-62. PubMed ID: 3458297
[TBL] [Abstract][Full Text] [Related]
37. Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration.
Brittenham GM
Semin Hematol; 1990 Apr; 27(2):112-6. PubMed ID: 2190317
[No Abstract] [Full Text] [Related]
38. Evaluation of transferrin and gallium-pyridoxal isonicotinoyl hydrazone as potential therapeutic agents to overcome lymphoid leukemic cell resistance to gallium nitrate.
Chitambar CR; Boon P; Wereley JP
Clin Cancer Res; 1996 Jun; 2(6):1009-15. PubMed ID: 9816262
[TBL] [Abstract][Full Text] [Related]
39. A study of the mechanism of action of pyridoxal isonicotinoyl hydrazone at the cellular level using reticulocytes loaded with non-heme 59Fe.
Huang AR; Ponka P
Biochim Biophys Acta; 1983 Jun; 757(3):306-15. PubMed ID: 6849979
[TBL] [Abstract][Full Text] [Related]
40. Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes.
Ponka P; Schulman HM; Wilczynska A
Biochim Biophys Acta; 1982 Oct; 718(2):151-6. PubMed ID: 7138909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
